Use of partial nephrectomy (PN) in T3 renal cell carcinoma (RCC) is controversial.
To evaluate quality outcomes of robot-assisted PN (RAPN) for clinical T3a renal masses (cT3aRM).
This was a retrospective multicenter analysis of patients with cT3aN0M0 RCC who underwent RAPN.
The primary endpoint was a trifecta composite outcome of negative surgical margins, warm ischemia time (WIT) ≤25 min, and no perioperative complications. The optimal outcome was defined as achieving this trifecta and ≥90% preservation of the estimated glomerular filtration rate (eGFR) and no stage upgrading of chronic kidney disease. Multivariable analysis (MVA) identified risk factors associated with lack of the optimal outcome. Kaplan-Meier analysis was conducted for survival outcomes.
Analysis was conducted for 157 patients (median follow-up 26 mo). The median tumor size was 7.0 cm (interquartile range [IQR] 5.0-7.8) and the median RENAL score was 9 (IQR 8-10). Median estimated blood loss (EBL) was 242 ml (IQR 121-354) and the median WIT was 19 min (IQR 15-25). A total of 150 patients (95.5%) had negative margins. Complications were noted in 25 patients (15.9%), with 4.5% having Clavien grade 3-5 complications. The median change in eGFR was 7 ml/min/1.72 m2, with ≥90% eGFR preservation in 55.4%. The trifecta outcome was achieved for 64.3% and the optimal outcome for 37.6% of the patients. MVA revealed that greater age (odds ratio [OR] 1.06; p = 0.002), increasing RENAL score (OR 1.30; p = 0.035), and EBL >300 ml (OR 5.96, p = 0.006) were predictive of failure to achieve optimal outcome. The 5-yr recurrence-free survival, cancer-specific survival, and overall survival, were 82.1%, 93.3%, and 91.3%, respectively. Limitations include the retrospective design.
RAPN for select cT3a renal masses is feasible and safe, with acceptable quality outcomes. Further investigation is requisite to delineate the role of RAPN in cT3a RCC.
Robot-assisted partial nephrectomy in patients with stage 3a kidney cancer provided acceptable survival, functional, and morbidity outcomes in the hands of experienced surgeons, and may be considered as an option when clinically indicated.
European urology focus. 2020 Nov 25 [Epub ahead of print]
Kendrick Yim, Monish Aron, Koon H Rha, Giuseppe Simone, Andrea Minervini, Ben Challacombe, Luigi Schips, Francesco Berardinelli, Giuseppe Quarto, Reza Mehrazin, Devin Patel, Sunil Patel, Ahmet Bindayi, Akbar N Ashrafi, Mihir Desai, Ali Alqahtani, Michele Gallucci, Jay Sulek, Andrea Mari, Nicolo De Luyk, Uzoma Anele, Riccardo Autorino, Francesco Porpiglia, Chandru P Sundaram, Inderbir S Gill, Sisto Perdona, Ithaar H Derweesh
Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA., Urological Institute, University of Southern California, Los Angeles, CA, USA., Urological Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea., Department of Urology, Regina Elena National Cancer Institute, Rome, Italy., Department of Urology, University of Florence, Careggi Hospital, Firenze, Italy., Department of Urology, Guys and St. Thomas' NHS Foundation Trust, London, UK., Department of Urology, Annunziata Hospital, G. D'Annunzio University, Chieti, Italy., Division of Urology, IRCCS Fondazione G. Pascale, Naples, Italy., Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Department of Urology, Indiana University, Indianapolis, IN, USA., Division of Urology, VCU Health System, Richmond, VA, USA., Division of Urology, San Luigi Hospital, University of Turin, Orbassano, Italy., Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA. Electronic address: .